Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Autor:	Joel S Hayflick, Vivek Subbiah, Frank Tsai, C. Le Tourneau, Hua Fang, Lawrence Fong, Maulik Patel, Mustafa Khasraw, Antoine Hollebecque, Anthony W. Tolcher, Steven Kao, Jason J. Luke, Fabrice Barlesi, Frances Fan, Karen Kelly, Philippe A. Cassier, Ki Y Chung, William R Henner, Kathryn Allaire, Michael A. McDevitt
Rok vydání:	2019
Předmět:	Brachial Plexus Neuritis Oncology medicine.medical_specialty CD40 biology business.industry Hematology Phase i study Pharmacokinetics Internal medicine Visual accommodation Pharmacodynamics medicine biology.protein Mesothelin In patient business
Zdroj:	Annals of Oncology. 30:v498-v499
ISSN:	0923-7534
DOI:	10.1093/annonc/mdz253.046
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1951337d31290ec5544b207322653658 https://doi.org/10.1093/annonc/mdz253.046 Zobrazit plný text záznamu